Merck KGaA (FRA:MRK) has been given a €103.00 ($119.77) price target by equities research analysts at Independent Research in a report issued on Tuesday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the healthcare company’s stock. Independent Research’s price target would indicate a potential upside of 7.70% from the stock’s current price.
Other research analysts also recently issued reports about the stock. Kepler Capital Markets set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, January 24th. Sanford C. Bernstein set a €105.00 ($122.09) target price on shares of Merck KGaA and gave the company a “buy” rating in a research report on Tuesday, February 5th. UBS Group set a €115.00 ($133.72) target price on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, March 7th. Finally, Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the company a “buy” rating in a research report on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of €101.15 ($117.62).
FRA MRK opened at €95.64 ($111.21) on Tuesday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: Diversification For Individual Investors
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.